about
Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer.Sulfurtransferase and thioredoxin specifically interact as demonstrated by bimolecular fluorescence complementation analysis and biochemical testsWhole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltrationNeoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress.Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer.FOXP3 expression in tumor cells and implications for cancer progression.Expression and prognostic significance of the autoimmune regulator gene in breast cancer cells.Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers.Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge.Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab.PDGFRβ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells.Maspin influences response to doxorubicin by changing the tumor microenvironment organization.Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation.Radiation effects on development of HER2-positive breast carcinomas.Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host.FOXP3 expression and overall survival in breast cancer.Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors.HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacyWound Healing Fluid Reflects the Inflammatory Nature and Aggressiveness of Breast TumorsTumor Extracellular Matrix Remodeling: New Perspectives as a Circulating Tool in the Diagnosis and Prognosis of Solid TumorsExtracellular matrix proteins as diagnostic markers of breast carcinomaCombined targeting of EGFR and HER2 against prostate cancer stem cellsInfiltrating mast cell-mediated stimulation of estrogen receptor activity in breast cancer cells promotes the luminal phenotypeExploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME TrialModulation of Pulmonary Microbiota by Antibiotic or Probiotic Aerosol Therapy: A Strategy to Promote Immunosurveillance against Lung MetastasesLocal Administration of Caloric Restriction Mimetics to Promote the Immune Control of Lung MetastasesEarly immune modulation by single-agent trastuzumab as a marker of trastuzumab benefitStromal responses among carcinomas--letter
P50
Q33737058-CB18B091-B970-4C7B-B0DD-FB98950AFA0CQ35852017-B129D703-74DB-4923-9279-F9B01E617698Q36414012-59834DE0-8EB8-459F-8742-08533D0EF10FQ36618752-78D5609E-EDCC-4143-9742-C59B1202F43BQ36729376-1B871269-B07C-400C-AD4C-5ADD87FC5FF7Q36922053-68535FE8-C4F0-4BB7-AD0E-DE3FB3646D83Q38016804-6F8AE46D-8572-4FEB-B960-0D39121A6244Q38740298-C51A5682-3113-4584-856E-8A9DD28EA4C2Q38742948-BF87E8B4-B1D3-43E1-BF08-DE43E3251365Q38786102-D6A3C652-D350-4FBD-A011-29D55283A183Q38962338-A979892E-5FA1-4F77-9F1F-6A906450F7D5Q39002862-B6FA5147-05FC-4046-A586-1B1533E2FF43Q39062271-808F3F1D-338B-43CF-92E3-B3FA14046ADAQ39166198-28A6FE70-8294-46DB-A6DD-FF0B5200017DQ40187976-1EF84258-0838-46D6-B032-A1FB123D9152Q48102534-9FB618F0-2462-4154-A001-66C6FB9052BDQ51789764-E1F4A624-73D3-4A0E-B73A-492F0723E031Q54678855-84EEEFEE-D71A-4572-BFDE-2EF9F75C3667Q62604186-D147E1F1-41F1-4DD9-9E88-1BB8718B3145Q64245148-EA8E4675-C956-4A14-B47D-BC58F26EB318Q64246051-919C22BC-B6DB-4474-A14C-D20114F3BADCQ88009805-A5AACCEE-42A5-4A26-9B09-EA0E7F7F1890Q89847014-35C84A10-A2DB-4FA2-8390-704D8A44EF6EQ90369537-0BE14D39-E7CC-47A4-ADD3-9B5A88E42B82Q90928136-6844E1F5-16B4-4955-A547-3027445579ADQ91770385-5E63A2B0-B51E-4CE3-9A19-4A066089C3C7Q92007672-91DBADBC-54B8-40AC-BFBF-4F1692032B3BQ93381916-89306C01-A261-46F1-A6BC-1F957A53F11BQ95561230-747DA4C3-B78A-4486-A469-75AF85B6628E
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Tiziana Triulzi
@ast
Tiziana Triulzi
@en
Tiziana Triulzi
@es
Tiziana Triulzi
@nl
type
label
Tiziana Triulzi
@ast
Tiziana Triulzi
@en
Tiziana Triulzi
@es
Tiziana Triulzi
@nl
prefLabel
Tiziana Triulzi
@ast
Tiziana Triulzi
@en
Tiziana Triulzi
@es
Tiziana Triulzi
@nl
P106
P1153
23490657500
P31
P496
0000-0003-3050-8676